University of Virginia Health System
University of Virginia Health System
Charlottesville, Virginia, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06703073 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701682 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701669 | |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Lung Injury, Respiration Disorders, acute lung injury, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-07-31 | NCT06701656 | |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-01-29 | NCT04965493 |